Erstellt von fchar99
Alnylam Pharmace. diskutieren
Alnylam Pharmace.
WKN: A0CBCK / Symbol: ALNY / Name: Alnylam Pharms / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /
351,60 €
1,59 %
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at BMO Capital Markets from $300.00 to $360.00. They now have an "outperform" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Needham & Company LLC from $320.00 to $377.00. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Jefferies Financial Group Inc. from $328.00 to $384.00. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Bank of America Corporation from $336.00 to $359.00. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Citigroup Inc. from $364.00 to $404.00. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at JPMorgan Chase & Co. from $338.00 to $348.00. They now have an "overweight" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating and a $385.00 price target on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is now covered by analysts at Raymond James Financial, Inc.. They set an "outperform" rating and a $370.00 price target on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Needham & Company LLC from $377.00 to $478.00. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at UBS Group AG from $403.00 to $550.00. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) was upgraded by analysts at Oppenheimer Holdings, Inc. from a "market perform" rating to an "outperform" rating. They now have a $490.00 price target on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at HC Wainwright from $500.00 to $570.00. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target raised by analysts at Citigroup Inc. from $527.00 to $583.00. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $570.00 price target on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) was given a new $470.00 price target on by analysts at BMO Capital Markets. They now have an "outperform" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target raised by analysts at Evercore ISI from $280.00 to $515.05. They now have an "outperform" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $504.00 to $566.00. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target raised by analysts at Bank of America Corporation from $453.00 to $520.00. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target raised by analysts at Royal Bank Of Canada from $435.00 to $500.00. They now have an "outperform" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target raised by analysts at Stifel Nicolaus from $441.00 to $495.00. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Neueste Beiträge
Citigroup_Inc_ in Northrop Grumman Corp. diskutieren